CD47 was first identified as a tumor antigen on human ovarian cancer in the 1980s.

They could therefore be used to vaccinate against viral, bacterial, protozoan, and tumor antigens.

But he added that such "cancer vaccines based on tumor antigens are currently more a hope than a reality."

An increasing number of tumor antigens have been identified [ 1 ] .

This follows recent knowledge that cancer cells may express certain unique tumor antigens.

The next step is the identification of lymphocytes in a patient that may recognize tumor antigens.

Detailed explanations of these tumor antigens can be found in Abbas and Lichtman, 2005.

This occurs because most tumor antigens are not essential for tumor growth.

The modern classification of tumor antigens is based on their molecular structure and source.

Certain tumor antigens are thus used as tumor markers.